A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients With Grade 3A High-risk Follicular Lymphoma
Active, not recruitingOBSERVATIONAL
Enrollment
37
Participants
Timeline
Start Date
May 1, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Conditions
Follicular Lymphoma
Trial Locations (1)
450000
the First Affiliated Hospital of zhengzhou University, Zhengzhou
All Listed Sponsors
lead
Zhengzhou University
OTHER
NCT06742879 - A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients With Grade 3A High-risk Follicular Lymphoma | Biotech Hunter | Biotech Hunter